CN Patent

CN102838590B — 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途

Assigned to HANGZHOU HUADONG MEDICINE GROUP NEW MEDICINE RESEARCH INSTITUTE CO., LTD. · Expires 2014-07-09 · 12y expired

What this patent protects

本发明涉及一种新型的氨基喹唑啉衍生物及其在制备预防和/或治疗抗恶性肿瘤药物中的用途。本发明的氨基喹唑啉类化合物是理想的高效双重非可逆性EGFR及HER2激酶抑制剂，可用于治疗或预防乳腺癌、卵巢癌、胃肠癌、食管癌、肺癌、头颈部鳞癌、胰腺癌、表皮鳞癌、前列腺癌、神经胶质瘤和鼻咽癌等多种恶性肿瘤疾病。

USPTO Abstract

本发明涉及一种新型的氨基喹唑啉衍生物及其在制备预防和/或治疗抗恶性肿瘤药物中的用途。本发明的氨基喹唑啉类化合物是理想的高效双重非可逆性EGFR及HER2激酶抑制剂，可用于治疗或预防乳腺癌、卵巢癌、胃肠癌、食管癌、肺癌、头颈部鳞癌、胰腺癌、表皮鳞癌、前列腺癌、神经胶质瘤和鼻咽癌等多种恶性肿瘤疾病。

Drugs covered by this patent

afatinib-dimaleate (AFATINIB DIMALEATE)

Patent Metadata

Patent number: CN102838590B
Jurisdiction: CN
Classification: —
Expires: 2014-07-09
Drug substance claim: No
Drug product claim: No
Assignee: HANGZHOU HUADONG MEDICINE GROUP NEW MEDICINE RESEARCH INSTITUTE CO., LTD.
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.